Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Skin Neoplasms 1Prostatic Neoplasms 1Oligodendroglioma 1Melanoma 1Lymphoma, Follicular 1Lung Neoplasms 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Temozolomide 17Radiotherapy 5Bevacizumab 5Filgrastim 4vocimagene amiretrorepvec 3sargramostim 3etoposide phosphate 3antineoplaston AS 2-1 3antineoplaston A10 3Surgical Procedures, Operative 3O(6)-benzylguanine 3Melphalan 3Lomustine 3Flucytosine 3Dynamic Contrast Enhanced Magnetic Resonance Imaging 3Carmustine 3Aminolevulinic Acid 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tovorafenib 2palbociclib 2cabozantinib 2Vorinostat 2Topotecan 2Thiotepa 2Radiotherapy, Intensity-Modulated 2Perfusion Magnetic Resonance Imaging 2Magnetic Resonance Spectroscopy 2Irinotecan 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Astrocytoma × varlilumab × Clear all
NCT02924038 2024-06-14

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

University of California, San Francisco

Phase 1 Terminated
14 enrolled 10 charts
CNSLymphoid

Astrocytoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡